ClinicaliQ Trial Snapshot
- Phase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2) — Active Not Recruiting • Phase III • Rheumatology • NCT05624749.
- Monthly ianalumab injections added to standard lupus treatment reduced disease activity better than placebo.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The trial will evaluate efficacy, safety and tolerability of ianalumab compared to placebo, given as monthly subcutaneous (s.c.) injection on top of standard-of-care (SoC) treatment in participants with active systemic lupus erythematosus (SLE). Conditions: Systemic Lupus Erythematosus Interventions: ianalumab, placebo Lead Sponsor: Novartis Pharmaceuticals Planned Enrollment: 288 participants